Bayesian Analysis of Gemcitabine Trials in Nasopharyngeal Cancer
Author Information
Author(s): Tan S-B, Machin D, Tai B-C, Foo K-F, Tan E-H
Primary Institution: National Cancer Centre Singapore
Hypothesis
How could a Bayesian approach affect the design, analysis, and interpretation of Phase II trials of gemcitabine in metastatic nasopharyngeal carcinoma?
Conclusion
The Bayesian approach provided interpretations that were generally in agreement with frequentist analysis but allowed for more useful insights regarding trial results.
Supporting Evidence
- The Bayesian analysis allowed for the incorporation of external information, enhancing the interpretation of trial results.
- Results indicated a 62% chance of the true response proportion being between predefined thresholds for the chemotherapy-naïve group.
- The previously treated group showed a 99% probability of exceeding the desired response rate.
Takeaway
This study looked at how using a different math method called Bayesian analysis can help understand how well a cancer drug works in patients.
Methodology
The study analyzed two Phase II trials using both frequentist and Bayesian statistical methods to evaluate the efficacy of gemcitabine.
Potential Biases
The subjective nature of Bayesian methods may introduce bias based on prior beliefs.
Limitations
The study did not elicit prior opinions from investigators before the trials began, which may affect the Bayesian analysis.
Participant Demographics
Patients included both chemotherapy-naïve and previously treated individuals with metastatic nasopharyngeal carcinoma.
Statistical Information
Confidence Interval
95% CI: 14 to 48% for chemotherapy-naïve group; 95% CI: 31 to 66% for previously treated group.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website